News | July 06, 2024
Nephro Care India lists at 90% premium
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The first such initiative under the MoU will involve establishing a Centre of Excellence for Renal Sciences at the Tomo Riba Institute of Health & Medical Sciences (TRIHMS)
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
Subscribe To Our Newsletter & Stay Updated
